Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Blood Advances|January 26, 2021
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamideBenedetta Rambaldi, Haesook T Kim, Carol Reynolds, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Blood Advances|September 4, 2020
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemiaHaesook T Kim, Conner J Shaughnessy, Sharmila C Rai, et al.
Blood|December 17, 2015
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHDAna C Alho, Haesook T Kim, Marie J Chammas, et al.
Blood Advances|September 28, 2021
Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitutionKatie Maurer, Haesook T Kim, Thomas M Kuczmarski, et al.
Transplantation and Cellular Therapy|September 23, 2025
Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell TransplantationJessica S Little, Kyle M Hebert, Donna S Neuberg, et al.
Transplantation and Cellular Therapy|January 29, 2023
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell TherapiesSarah Nikiforow, Matthew J Frigault, Noelle V Frey, et al.
Haematologica|April 29, 2022
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantationBenedetta Rambaldi, Haesook T Kim, Yohei Arihara, et al.
Blood Advances|April 3, 2019
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host diseaseJennifer S Whangbo, Haesook T Kim, Sarah Nikiforow, et al.
Blood Advances|April 27, 2022
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host diseaseJennifer S Whangbo, Sarah Nikiforow, Haesook T Kim, et al.
Pageof 13